Summary & Overview
HCPCS P9044: Plasma, Cryoprecipitate Reduced, Each Unit
HCPCS Level II code P9044 denotes a single unit of plasma that has been cryoprecipitate reduced. This blood component code is relevant across acute care and outpatient transfusion settings where plasma is needed but cryoprecipitate has been removed for separate clinical use. Nationally, accurate coding of blood products supports proper clinical documentation, inventory tracking, and payer adjudication for transfusion services.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for P9044, typical sites of service, and which payers commonly process claims for this blood product. The publication outlines benchmark and coverage considerations, common billing modifiers associated with transfusion services, and related coding notes where available. Where specific payer policy details or additional crosswalks are not provided, the summary notes that data was not available in the input.
This document is intended to inform billing staff, clinical coders, and policy analysts about the clinical nature of P9044, the service settings in which it is used, and the payer landscape relevant to processing claims for cryoprecipitate reduced plasma units.
Billing Code Overview
HCPCS Level II code P9044 describes plasma, cryoprecipitate reduced, each unit. This code represents the provision of a unit of plasma that has had cryoprecipitate removed, typically used when transfusion of plasma is required but cryoprecipitate components (such as fibrinogen) are not desired or have been removed for other clinical uses.
Service Type: Blood product transfusion / blood component therapy
Typical Site of Service: Hospital inpatient or outpatient transfusion centers, ambulatory surgery centers, and other clinical settings where blood products are administered
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient receiving P9044 is an adult or pediatric inpatient requiring plasma component therapy where cryoprecipitate has been removed (cryoprecipitate-reduced plasma) to avoid excess fibrinogen/ factor VIII while providing other plasma proteins and coagulation factors. A realistic scenario: a 62-year-old male with end-stage liver disease admitted for acute variceal bleeding undergoes volume resuscitation and correction of coagulopathy. The transfusion medicine team orders plasma products; the blood bank issues P9044 units when the clinical goal is to replace clotting factors without raising fibrinogen substantially (for example, when prior hyperfibrinogenemia or concern for fluid overload exists or when cryoprecipitate has been reserved for a separate indication).
The clinical workflow: clinician documents indication and orders plasma in the electronic medical record; the transfusion service reviews indications and patient ABO compatibility; blood bank issues P9044 with appropriate labeling and transfusion instructions; bedside nursing verifies patient identity, obtains baseline vitals, starts transfusion, monitors for transfusion reactions, and documents volume/units transfused and patient response. Pharmacy or transfusion medicine may be consulted for dose calculations based on weight and target coagulation parameters (INR, PT). Billing and coding capture P9044 per unit dispensed, with applicable modifiers documented on the claim when relevant (for example, split/shared services or unusual service circumstances).
Coding Specifications
| Modifier | Description |
|---|